Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF and Autologous Bone Marrow Transplantation for CML
NCT00011934Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 1998
- Primary completion
- Aug 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in chronic myeloid leukemia (CML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Event-Free Survival at 1 year and Toxicity. Started May 1998; status: completed.
02
Drugs
sargramostim
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00011934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00011934.